Published in Am J Pathol on January 01, 2001
Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40
Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A (2004) 2.88
The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener (2007) 1.81
Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol (2004) 1.70
Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol (2004) 1.70
Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation (2005) 1.45
BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem (2009) 1.16
The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond. Front Physiol (2012) 1.09
BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology. Neurotox Res (2011) 0.90
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease. Curr Genomics (2007) 0.90
Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice. J Biol Chem (2004) 0.89
Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. Neuroimage (2010) 0.87
CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition. J Neurosci (2014) 0.84
Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am J Pathol (2002) 0.83
Reduction of β-amyloid and γ-secretase by calorie restriction in female Tg2576 mice. Neurobiol Aging (2014) 0.81
The Guinea Pig as a Model for Sporadic Alzheimer's Disease (AD): The Impact of Cholesterol Intake on Expression of AD-Related Genes. PLoS One (2013) 0.79
Asynchronous evolutionary origins of Aβ and BACE1. Mol Biol Evol (2013) 0.76
Cerebrospinal fluid BACE1 activity and brain amyloid load in Alzheimer's disease. ScientificWorldJournal (2012) 0.75
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature (1999) 8.28
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (1999) 5.77
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A (1997) 5.66
Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature (1999) 5.48
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A (1997) 4.92
Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron (1997) 4.49
APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol (1997) 4.29
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet (1997) 4.11
Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci (1999) 3.77
Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem (1999) 3.20
Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci (1997) 2.91
Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci (1996) 2.69
Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol (2000) 2.21
BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci U S A (2000) 1.64
Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem (2000) 1.36
Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol (2000) 1.13
Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Ann Neurol (1999) 1.05
Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat Neurosci (1999) 1.05
Differential regional and cellular distribution of beta-amyloid precursor protein messenger RNAs containing and lacking the Kunitz protease inhibitor domain in the brain of human, rat and mouse. Neuroscience (1993) 0.98
In situ hybridization analysis of presenilin 1 mRNA in Alzheimer disease and in lesioned rat brain. Proc Natl Acad Sci U S A (1996) 0.94
Alzheimer disease: mouse models pave the way for therapeutic opportunities. Arch Neurol (2000) 0.89
Presenilin-1, amyloid precursor protein and amyloid precursor-like protein 2 mRNA levels in human superior frontal cortex during aging. Neurosci Lett (1997) 0.85
Developmental regulation of presenilin mRNA expression parallels notch expression. J Neuropathol Exp Neurol (1997) 0.83
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet (1998) 7.26
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science (1984) 6.86
Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol (2000) 6.40
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex (1992) 5.57
MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology (2002) 4.67
Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology (1992) 4.52
APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol (1997) 4.29
Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology (2004) 4.00
Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron (1993) 3.92
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci (1999) 3.85
Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol (1995) 3.60
Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med (1998) 3.23
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci (1997) 2.91
Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol (2000) 2.78
Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med (2001) 2.75
BNaC1 and BNaC2 constitute a new family of human neuronal sodium channels related to degenerins and epithelial sodium channels. Proc Natl Acad Sci U S A (1997) 2.53
Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med (1996) 2.43
LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell (1995) 2.37
Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci U S A (1999) 2.36
Perforant pathway changes and the memory impairment of Alzheimer's disease. Ann Neurol (1986) 2.33
Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci (1993) 2.27
Hippocampal formation: anatomy and the patterns of pathology in Alzheimer's disease. Prog Brain Res (1990) 2.26
Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol (2000) 2.21
Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience (2006) 2.19
Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci (2001) 2.12
Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci (1993) 2.09
Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem (2007) 2.09
Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem (2000) 2.00
Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol (2001) 1.96
Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology (1996) 1.89
Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 1.87
Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology (2011) 1.83
Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol (1999) 1.81
Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience (2001) 1.80
Reliability of MRI-derived cortical and subcortical morphometric measures: effects of pulse sequence, voxel geometry, and parallel imaging. Neuroimage (2008) 1.75
Isolation and characterization of APLP2 encoding a homologue of the Alzheimer's associated amyloid beta protein precursor. Nat Genet (1993) 1.72
Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J Biol Chem (2000) 1.72
H. M.'s medial temporal lobe lesion: findings from magnetic resonance imaging. J Neurosci (1997) 1.71
Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab (1998) 1.71
Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol (1998) 1.67
Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol (2000) 1.66
Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol (1996) 1.66
The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A (2000) 1.65
Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry (1991) 1.64
Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem (1996) 1.61
Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke (1996) 1.60
Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease. AJNR Am J Neuroradiol (2012) 1.57
Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology (1998) 1.56
Notch1 inhibits neurite outgrowth in postmitotic primary neurons. Neuroscience (1999) 1.54
Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J Neuropathol Exp Neurol (2001) 1.53
In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol (2003) 1.50
Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol (1998) 1.47
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol (1999) 1.43
Role of the beta-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia. J Virol (1998) 1.38
Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice. J Neurosci (1997) 1.38
Assessment of amyloid beta-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. Am J Hum Genet (1992) 1.37
Entorhinal cortex pathology in Alzheimer's disease. Hippocampus (1991) 1.36
Reduced apolipoprotein epsilon 4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals. Neurology (1994) 1.35
Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J Neuropathol Exp Neurol (1996) 1.35
Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling. J Neurochem (2000) 1.34
Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med (1987) 1.34
Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol (1999) 1.33
Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. Am J Pathol (1996) 1.31
Feature article: are neurons lost from the primate cerebral cortex during normal aging? Cereb Cortex (1998) 1.29
Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol (1998) 1.29
Problems in the assessment of psychosomatic conditions in Social Security benefits and related commercial schemes. J Psychosom Res (1995) 1.28
Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol (2000) 1.27
Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem (1993) 1.26
Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology (2005) 1.26
Alzheimer disease therapeutics. J Neuropathol Exp Neurol (2001) 1.25
MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD. Neurology (2008) 1.24
Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem (1993) 1.24
Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology (1999) 1.24
Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol (1995) 1.23
Alpha2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem (1999) 1.23
Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol (2001) 1.22
Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. Proc Natl Acad Sci U S A (1994) 1.22
Abeta associated neuropil changes: correlation with neuronal loss and dementia. J Neuropathol Exp Neurol (1998) 1.20
Progressive aphasia in a patient with Pick's disease: a neuropsychological, radiologic, and anatomic study. Neurology (1990) 1.19
Distribution of the messenger RNA for the extracellularly regulated kinases 1, 2 and 3 in rat brain: effects of excitotoxic hippocampal lesions. Neuroscience (1997) 1.18
alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol (2000) 1.17
Notch is expressed in adult brain, is coexpressed with presenilin-1, and is altered in Alzheimer disease. J Neuropathol Exp Neurol (1998) 1.17
Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. Neurosci Lett (1994) 1.17
Description of microcolumnar ensembles in association cortex and their disruption in Alzheimer and Lewy body dementias. Proc Natl Acad Sci U S A (2000) 1.16
Temporoparietal MR imaging measures of atrophy in subjects with mild cognitive impairment that predict subsequent diagnosis of Alzheimer disease. AJNR Am J Neuroradiol (2008) 1.15
Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci (1996) 1.15
Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J Neurochem (1996) 1.15
Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology (1999) 1.15
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci (1998) 1.14